Related Experiment Video

Updated: Jul 2, 2025

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target
11:34

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target

Published on: May 10, 2022

2.2K

Novel therapeutic approaches for the management of hepatitis infections

Aswin Damodaran1, Subin Mary Zachariah1, Sreeja Chandrasekharan Nair1

  • 1Amrita School of Pharmacy, Amrita Vishwa Vidyapeetham, AIMS Health Science Campus, Kochi, Kerala, 682041, India.

Therapeutic Delivery
|February 27, 2024
PubMed

Insights

Novel nanotechnology drug and vaccine delivery systems show promise for treating Hepatitis B (HBV) and Hepatitis C (HCV) infections, overcoming challenges with current therapies and enhancing immune responses.

Area of Science:

  • Hepatology and Viral Immunology
  • Nanomedicine and Drug Delivery

Background:

  • Hepatitis B virus (HBV) and Hepatitis C virus (HCV) infections are major global causes of illness and death.
  • Chronic hepatitis B (CHB) significantly increases the risk of liver cirrhosis, decompensation, and hepatocellular carcinoma (HCC).
  • Existing therapies for HBV and HCV face limitations such as poor tolerability and drug resistance.

Purpose of the Study:

  • To review current nanotechnology-based drug and vaccine delivery systems for HBV and HCV treatment.
  • To explore novel therapeutic strategies for inducing robust and stable antiviral immune responses.

Main Methods:

  • Literature review of recent advancements in nanotechnology for antiviral drug and vaccine delivery.
  • Analysis of nanotechnology-based carriers designed to target HBV and HCV infections.
  • Evaluation of studies focusing on immune response modulation through nanodelivery systems.

Main Results:

  • Nanotechnology offers innovative carriers for improved drug and vaccine delivery against HBV and HCV.
  • These systems have the potential to enhance therapeutic efficacy and overcome resistance issues.
  • Nanoparticle-based approaches may facilitate stronger and more durable antiviral immunity.

Conclusions:

  • Nanotechnology-based delivery systems represent a promising frontier for the treatment of HBV and HCV.
  • Further research and development are crucial to translate these nanotechnologies into effective clinical interventions.
  • Harnessing nanotechnology can lead to improved outcomes for patients with chronic viral hepatitis.

Keywords:
Hepatitis B virusanti-viral therapydrug deliverynanotechnologyvaccine delivery

More Related Videos

High-throughput Screening for Broad-spectrum Chemical Inhibitors of RNA Viruses11:34

High-throughput Screening for Broad-spectrum Chemical Inhibitors of RNA Viruses

Published on: May 5, 2014

13.8K
Development of a Hepatitis B Virus Reporter System to Monitor the Early Stages of the Replication Cycle09:35

Development of a Hepatitis B Virus Reporter System to Monitor the Early Stages of the Replication Cycle

Published on: February 1, 2017

13.3K

Related Concept Videos

Gastritis III: Clinical Manifestations and Management01:23

Gastritis III: Clinical Manifestations and Management

The clinical manifestations of gastritis can vary depending on the cause and type of gastritis, but some common symptoms may include the following.
Clinical manifestations of acute gastritis
The patient with acute gastritis may have a rapid onset of symptoms, such as epigastric pain or discomfort, dyspepsia, anorexia, hiccups, or nausea and vomiting, which can last from a few hours to a few days. Erosive or hemorrhagic gastritis may cause bleeding, which may manifest as blood in vomit or as...
248
Peptic Ulcer Disease IV: Management01:26

Peptic Ulcer Disease IV: Management

Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
92
Pleural Effusion II: Symptoms and Management01:28

Pleural Effusion II: Symptoms and Management

Pleural Effusion Overview
A pleural effusion is the abnormal collection of fluid between the parietal and visceral pleura layers of tissue that form the lining of the lungs and chest cavity. It can occur independently or due to surrounding parenchymal diseases, such as infection, malignancy, or inflammatory conditions.
Clinical Manifestations:
173
Chronic Pancreatitis II: Collaborative Care01:29

Chronic Pancreatitis II: Collaborative Care

The management of chronic pancreatitis is multifaceted, involving a comprehensive approach that includes thorough assessment, diagnostic testing, and a variety of management strategies.
Assessment:
90
Esophageal Varices-II: Clinical Features and Management01:28

Esophageal Varices-II: Clinical Features and Management

Esophageal varices often manifest as gastrointestinal bleeding episodes, presenting symptoms like hematemesis (vomiting of blood), hematochezia (passing fresh blood via the rectum), and melena (black, tarry stools). Other signs can include weight loss, anorexia, abdominal discomfort, jaundice, pruritus, altered mental status, and muscle cramps.
In the initial assessment, a thorough review of the patient's medical history is vital to identify risk factors such as liver disease, alcohol...
67
Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy01:16

Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy

Helicobacter pylori, a resilient gram-negative bacterium, can thrive in the stomach's harsh, acidic environment. Infection with H. pylori leads to a cascade of events within the stomach lining. One of the critical disruptions caused by this bacterium is the interference with somatostatin production, a hormone responsible for regulating acid secretion. This interference tips the balance, escalating acid secretion and diminishing bicarbonate levels. This imbalance compromises the defensive...
403